Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide
They’re the top producer in diabetic care, hoping to see this in the 250 US batch!
2 Likes
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products.
The company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. Products marketed to over 180 countries.
I opened a position in NVO earlier this month on the back of a post-earnings decline.
I like its core diabetes business and I’m optimistic about the potential of its weight-loss drugs.
As the Barron’s article below points out, this could be an annual trillion dollar market in the US – if insurers can be persuaded to pay for it on a preventative basis.
I might be a bit late to the party here, but after the UK have authorised the use of Novos’ weight loss inj, I’m hoping for a little extra return on my investment. I think this will hype up quite rapidly. *disclaimer - I am not a seasoned trader, so please do your own research!
Just jumped on my watchlist after this news.
Seems to be doing big things with both obesity and diabetes.
3 Likes
This is relatively big news for Novo Nordisk. T’other day, I read that NVO briefly became Europe’s most valuable company over LVMH. It’s marketcap has also inched ahead of Denmark’s yearly GDP. 
1 Like